Newsletter | October 14, 2021

10.14.21 -- Enhancing Bioavailability For Early Development Phase Molecules

 
The Next Generation ODT
 

Get an overview of the Zydis ODT technology, including new ways to administer peptides and vaccines, and the next generation ODT technology, Zydis Ultra, which incorporates coated APIs for enhanced taste masking at a higher dose strength.

NMR And Mass Spectrometry In Pharmaceutical Development
 

Together, nuclear magnetic resonance (NMR) and MS analysis can definitively identify reference standards, active pharmaceutical ingredients (APIs), or final drug product composition.

Expediting A Promising New Therapy
 

A biotech exploring novel therapeutics for neuroscience indications developed a promising new chemical entity to treat a severe pediatric genetic disease. Softgel technology expedited its Phase II/III clinical trial.

A Structured Approach To Enhancing Bioavailability For Early Development Phase Molecules
 

An agile, parallel, and cross-functional approach, powered by a silo-free organization structure, will help in bringing an effective dosage form faster to market. Explore the feasibility of this approach and the tools and processes that can help materialize it.